Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial

Boever, Erika H. De; Ashman, Claire; Cahn, Anthony; Locantore, Nicholas; Overend, Philip; Pouliquen, Isabelle; Serone, Adrian; Wright, Tracey J.; Jenkins, Mair; Panesar, Inderpal S.; Thiagarajah, Sivayogan S.; Wenzel, Sally E.

doi:10.1016/j.jaci.2014.01.002

Cited by 133 publications

(92 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anrucinzumab is a humanised monoclonal antibody to IL-13. DeBoever FH et al [39] used anrucinzumab to treat 237 patients with severe asthma, who were receiving the maximum dose of ICS. There was a lack of positive change in regards to the eosinophil content and IgE levels.…”

Section: Anti-cytokine Therapymentioning

confidence: 99%

The Role of Cytokines in the Pathogenesis of Bronchial Asthma and the Possibilities of Anti-Cytokine Therapy

Gb¹

2017

JLPRR

View full text Add to dashboard Cite

Submit Manuscript | http://medcraveonline.com HT and IHD (comparison group) and 20 were healthy subjects. All patients signed informed consent before the study. The Protocol of the study was passed review and was approved by the local ethics Committee of our University. The presence of IgE was determined to tick and house dust allergens, as well as the combined allergens of grass pollen, trees, weeds and flowers, S. pneumon, H. influenzae, and N. rerflava. The following cytokines were investigated: IL-4, IL-6, IL-10, IL-17, IFNγ, TNFα. All patients were examined during disease exacerbation. The INFP and ATP were determined for each subject. The results of the study of CK levels and CK combinations, the so-called cytokine profile, indicate that they cannot be used for clinical diagnosis, including nosological diagnosis, the assessment of disease severity, and for selecting individual therapy, including anti-cytokine medications.The incredible heterogeneity of bronchial asthma (BA) is becoming more and more clear. More than 30 years ago, in 1977, we pointed out the existence of seven clinical and pathogenetic types of BA in patients, subsequently called the following phenotypes: infection-dependent, atopic, hormonal, neuropsychological, autoimmune, significant adrenergic imbalance, and primary bronchial hyperreactivity [1]. Individual methods of diagnosis and treatment were developed for each of these options, and the results of their testing have been repeatedly published. Subsequently, the phrase "primary bronchial hyperreactivity" was replaced with the idea of exercise-induced BA, peri-menstrual and aspirin-related clinical and pathogenetic types (phenotypes) of BA. The methods of individual diagnosis and treatment continued to improve and their efficacy continued to increase.Inhalation corticosteroids (ICS) are considered to be the most effective in the treatment of BA. However, in 5-10% of patients with BA, comprehensive treatment is ineffective even with the inclusion of ICS [2]. Although the percentage of patients resistant to ICS, is quite low, they make up 50% of the overall cost of treatment for patients with BA [3]. The insufficient treatment efficacy of existing methods for a group of patients with BA is a reason for examining the BA phenotypes and the endotypes that form them. Knowledge of the mechanisms (endotypes) that form the phenotypes creates the prospects for developing new treatment methods, which take into account the individual characteristics of BA in a particular patient. A cluster analysis of two large European cohorts identified two phenotypes. The first refers to patients with early onset allergic BA, while the second comprises mainly women with late onset disease, without atopy, and with a high body mass index [4].Seven parameters were selected to classify the endotypes in patients with BA after the cluster analysis: clinical characteristics, biomarkers, lung physiology, genetics, histopathology, epidemiology, and response to treatment. The following BA endotypes were proposed based o...

show abstract

Section: Anti-cytokine Therapymentioning

confidence: 99%

The Role of Cytokines in the Pathogenesis of Bronchial Asthma and the Possibilities of Anti-Cytokine Therapy

Gb¹

2017

JLPRR

View full text Add to dashboard Cite

show abstract

“…Приме-нение антагонистов IL13 лебрикизумаба и тралокину-маба при тяжелой бронхиальной астме в ряде исследо-ваний дало разочаровывающий результат. Отмечался лишь небольшой физиологический эффект, а симптомы и частота обострений сохранялись [34,35].…”

Section: моноклональные антителаunclassified

“…Выше мы отмечали разочаровывающие результа-ты применения лебрикизумаба (моноклональные анти-IL13 антитела) [34,35]. Дальнейшие исследования по-казали, что у пациентов с высоким сывороточным перио-стином по сравнению с больными, у которых его уровень был низким, применение лебрикизумаба сопровожда-лось выраженным улучшением функции легких (определя-ли ОФВ 1 ) [51].…”

Section: периостин как потенциальный маркер эозинофильного воспаленияunclassified

Potential Role of Serum Periostin in the Early Detection of Bronchial Asthma in Children

Sobotyuk¹,

Gaponenko²,

Бочанцев³

et al. 2016

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

АКТУАЛЬНОСТЬНи значительные достижения в диагностике бронхи-альной астмы (БА), ни внедрение в практику современных методов контроля и профилактики бронхиальной обструк-ции так и не привели к снижению заболеваемости, осо-бенно среди детского населения. B наши дни БА -наи-более распространенная хроническая форма патологии дыхательных путей в младшей возрастной группе [1,2].В конце XX -начале XXI века исследователи на экс-периментальных моделях убедительно показали, что Т хел перы второго типа (Th2) играют важнейшую роль в развитии аллергической БА, и с их активацией связаны

show abstract

“…Also antibodies neutralizing IL-9 (MEDI-528 [9]) or IL-13 (lebrikizumab [10], GSK679586 [11], IMA-026 [12]) were discontinued due to lack of efficacy in clinical asthma trials. While another IL-13 neutralizing antibody (tralokinumab [13]) is now tested phase III clinical trial, to date only anti-IL-5 antibodies (benralizumab [14], mepolizumab [15], reslizumab [16]) have been approved for treatment of severe persistent, allergic asthma with high eosinophil counts.…”

mentioning

confidence: 99%

Targeting cytokines in asthma therapy: could IL-37 be a solution?

Wegmann

2017

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial

Cited by 133 publications

References 41 publications

The Role of Cytokines in the Pathogenesis of Bronchial Asthma and the Possibilities of Anti-Cytokine Therapy

The Role of Cytokines in the Pathogenesis of Bronchial Asthma and the Possibilities of Anti-Cytokine Therapy

Potential Role of Serum Periostin in the Early Detection of Bronchial Asthma in Children

Targeting cytokines in asthma therapy: could IL-37 be a solution?

Contact Info

Product

Resources

About